The HOLiFOOD consortium is reimagining food safety risk assessment for the benefit of all stakeholders in the food chain ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the ...

Butyllithium reagents have wide-ranging applications across industries, often serving as polymerisation initiators or strong ...

Let’s check what we’ve heard and what we think we know against the science.

The need to ensure that the requisite level of preparedness precedes any important task. The job is broken down into small ...

Market valued at $72.4M in 2024, projected 7.30% CAGR growth driven by pharmaceutical API synthesis, food-grade ...

Alto Neuroscience receives US patent for ALTO-207; strengthens IP portfolio for patients with treatment-resistant depression: Mountain View, California Saturday, January 17, 2026, ...

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012DEE: 63.3% ...

The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.

DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central ...

DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n ...